A non-ablative treatment for benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) achieved durable ...

One such change, often less spoken about, is the enlargement of the prostate gland. This condition, known as Benign Prostatic Hyperplasia (BPH), is extremely common, especially in men above 50 years ...

About 10 weeks after it was approved, the Wegovy pill is now estimated to be part of the daily regimen of about 400,000 Americans. And the field of weight-loss treatment is on the verge of even more ...

Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced it has received U.S. Food and Drug Administration (FDA ...

The Urocross® Expander System is designed to remodel the obstructing prostatic lobes during the six-month indwell time and is ...

Procept BioRobotics today announced the international rollout of its next-generation Hydros robotic system for Aquablation therapy.

Prostate enlargement, which is called Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement and is common in ...

Clinically known as benign prostatic hyperplasia (BPH), enlarged prostate is a non‑cancerous condition that affects roughly half of men ages 51 to 60, with incidence increasing ...

Detailed price information for Procept Biorobotics Corp (PRCT-Q) from The Globe and Mail including charting and trades.

Asbestos-associated latency necessitates careful exposure history, and symptom patterns differ between pleural and peritoneal disease, often reflecting effusion or serosal thickening. Tissue ...